 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX004 in Cystic Fibrosis CF will be presented at the 44th European Cystic Fibrosis Conference ECFS. ECFS will be held from June 9-12, 2021. Our upcoming presentation at ECFS highlights the capability of our BOLT p 